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ABSTRACT: Structure-functional studies have recently revealed a
spectrum of diverse high-affinity nanobodies with efficient
neutralizing capacity against SARS-CoV-2 virus and resilience
against mutational escape. In this study, we combine atomistic
simulations with the ensemble-based mutational profiling of binding
for the SARS-CoV-2 S-RBD complexes with a wide range of
nanobodies to identify dynamic and binding affinity fingerprints and
characterize the energetic determinants of nanobody-escaping
mutations. Using an in silico mutational profiling approach for
probing the protein stability and binding, we examine dynamics and
energetics of the SARS-CoV-2 complexes with single nanobodies
Nb6 and Nb20, VHH E, a pair combination VHH E + U, a
biparatopic nanobody VHH VE, and a combination of the CC12.3
antibody and VHH V/W nanobodies. This study characterizes the
binding energy hotspots in the SARS-CoV-2 protein and complexes with nanobodies providing a quantitative analysis of the effects
of circulating variants and escaping mutations on binding that is consistent with a broad range of biochemical experiments. The
results suggest that mutational escape may be controlled through structurally adaptable binding hotspots in the receptor-accessible
binding epitope that are dynamically coupled to the stability centers in the distant binding epitope targeted by VHH U/V/W
nanobodies. This study offers a plausible mechanism in which through cooperative dynamic changes, nanobody combinations and
biparatopic nanobodies can elicit the increased binding affinity response and yield resilience to common escape mutants.
■ INTRODUCTION
Structural and functional studies of the SARS-CoV-2 infection
mechanisms have been largely focused on the viral spike (S)
glycoprotein that interacts with the host cell receptor ACE2
and produces a cascade of conformational changes that lead to
membrane fusion.1−3 The recent growth of cryo-EM structures
for the SARS-CoV-2 S proteins showed a remarkable diversity
of conformational changes of the S protein trimers in which S1
and S2 subunits can act synchronously to orchestrate a delicate
balance of stability and dynamics that governs functional
rearrangements of the prefusion and postfusion forms.4,5 The
conformational changes of the S protein trimers associated
with binding to ACE2 are executed through spontaneous
thermal movements of the N-terminal domain and the
receptor-binding domain (RBD) which fluctuates between
the RBD-down (closed) and the open RBD-up form.6−19
Functional and conformational plasticity of SARS-CoV-2 S
proteins and their ability to produce specific and precise
protein responses to binding have been revealed in the rapidly
expanding number of cryo-EM and X-ray spike complexes with
a wide range of neutralizing antibodies.20−28 These studies
have classified SARS-CoV-2 antibodies into several major
categories that prominently feature monoclonal antibodies that
target the receptor binding motif (RBM) region of the RBD
epitope.28−31 The recent structure-functional studies of the
SARS-CoV-2 S protein binding revealed the binding epitopes
and clarified basic recognition mechanisms for a number of
highly potent antibodies targeting the RBM region, which
include REGN10933, B38, CB6, CC12.3, and BD-236
antibodies.32−38 These pioneering studies also demonstrated
that antibody cocktails targeting different binding epitopes
could produce strong synergistic effects, leading to the stronger
neutralization profile and the improved resilience against
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antibody-induced mutations. Biochemical studies using deep
mutagenesis experiments have enabled comprehensive func-
tional mappings of mutational responses and characterized
patterns of mutational escape to many antibodies.39−42 These
illuminating experiments revealed that escape-resistant anti-
body cocktails can impose conformation-specific “breaks” on
the plasticity of the S protein and significantly restrict virus
“creativity” in finding the sites of immune escape that would
not deleteriously affect the protein stability and ACE2
binding.39−42 A comprehensive review of the SARS-CoV-2 S
mutational variants and mechanisms of immune escape
dissected the evolutionary and structural origins underlying
the impacts of mutations on antigenicity.43 This study
suggested several distinct mechanisms by which mutations
can alter the antigenic responses and elicit antibody evasion,
which included mutation-induced alteration of the binding
epitopes for antibodies, the increasing host receptor binding
avidity, changes in the glycosylation environment, and also
allosterically regulated structural and dynamic changes in the
spike protein.43 The global circulating mutants of the SARS-
CoV-2 S protein discovered through epidemiological surveil-
lance are often prominently featured in a wide range of
antibody-escaping mutational patterns.44−54 Many of these
circulating mutations have also been identified in deep
mutagenesis mapping experiments as escaping variants to a
wide range of highly potent class I and class II antibodies,
suggesting that virus can often evolve to evade antibody
binding by targeting flexible RBD regions sensitive to
binding.39−42
Nanobodies have shown an increasing promise in combating
escaping mutations.55−57 An ultrapotent nanobody Nb6
neutralizes SARS-CoV-2 by stabilizing the closed form of the
S protein and inhibiting binding with the ACE2 receptor.55
Another group of high-affinity nanobodies including Nb20 and
Nb21 can neutralize SARS-CoV-2 by targeting a dominant
epitope that overlaps with the ACE2 binding site.56 A number
of highly potent neutralizing nanobodies that resist circulating
variants of SARS-CoV-2 by targeting existing and novel
epitopes were recently unveiled.57 The cryo-EM structures
for different classes of nanobodies reported in this study
suggested the mechanisms of high affinity and neutralizing
activity that are based on the synergistic exploitation of distinct
epitopes using binding avidity effects.57 Another diverse group
of high-affinity nanobodies with an excellent neutralizing
activity against SARS-CoV-2 S protein that can effectively
combat resistance to common escape mutants featured
complementary binding to the nonoverlapping epitopes in
the RBD core and a more flexible RBM region.58 These studies
suggested that multimeric nanobody combinations can
significantly improve binding affinity via positive cooperativity
between binding sites that can drastically limit virus “options”
to find alternative mutational sites and allow for the reduction
of susceptibility to escape mutations.58
Protein engineering studies discovered several unique VH
binders that recognize two separate epitopes within the ACE2
binding interface with nanomolar affinity, leading to multi-
valent and biparatopic VH constructs with the markedly
increased affinity and neutralization potency to the SARS-CoV-
2 virus as compared to the standalone VH domain.59
Biochemical saturation mutagenesis and fluorescence-activated
cell sorting for mutant screening mapped patterns of escape
mutants for some of these nanobodies, indicating that
vulnerable sites were localized on the periphery of the
ACE2-binding site.60 A number of recently discovered
nanobodies with efficient neutralizing capacity and resilience
against mutational escape included VHH E nanobody targeting
the RBM-binding epitope and VHHs U, V, and W nanobodies
that bind to a distant cryptic epitope in the RBD.61−63 This
structure-functional “tour de force” investigation provided a
compelling evidence that synergistic cocktails of nanobodies
interacting with distinct RBD epitopes can efficiently suppress
the emergence of escape mutants that were resistant to
individual nanobodies.61 Of particular interest were biparatopic
VHH EV and VE nanobodies that were superior in preventing
mutual escape as compared to both individual nanobodies and
pair combinations VHH E + U, VHH E + V, and VHH E +
W.61 The two highly potent nanobodies H11-D4 and H11−
H4 recognize the same epitope that is immediately adjacent to
and partly overlapping with the ACE2-binding region.64 The
high-affinity nanobodies and nanobody cocktails consisting of
two noncompeting nanobodies can potently neutralize both
wild-type SARS-CoV-2 and the N501/D614G variants.65
Neutralization of SARS-CoV-2 by low-picomolar, hyper-
thermostable, and mutation-tolerant VHH nanobodies was
recently reported, unveiling the cryo-EM structures of a ternary
complex of the RBD with the fold-promoting nanobody
Re9F06 and the potently neutralizing Re5D06 nanobody that
bind synergistically to the opposite sides of the RBD and
occlude ACE binding.66 The tandem fusion of the Re5D06
nanobody binding to the RBM region and the hyper-
thermostable Re9F06 nanobody that binds to the RBD core
epitope produced a binding avidity effect unaffected by
immune-escape mutants K417N/T, E484K, N501Y, and
L452R.66 The recent fascinating discovery of nanobodies and
nanobody cocktails from camelid mice and llamas that
neutralize SARS-CoV-2 variants showed a remarkable ability
of multivalent nanobodies to combat escaping mutations
through synchronized avidity between binding epitopes.67
While a highly potent group of llama nanobodies (Nb17,
Nb19, and Nb56) directly target the ACE2-binding interface,
picomolar nanobodies from nanomouse (Nb12 and Nb30)
bind to a previously unappreciated conserved RBD epitope
outside of the ACE2-binding motif which is not accessible to
human antibodies, allowing for the mitigation of adverse effects
caused by escape mutations at E484 and N501 positions.67
These studies suggested that the biparatopic nanobodies can
be superior to monoclonal antibodies, single nanobodies, and
even conventional nanobody cocktails in combating escape
mutations by effectively leveraging binding avidity and
allosteric cooperativity mechanisms coupled with the reduced
entropic cost of binding to distinct epitopes.
Computer simulations have made important contributions
to our understanding of the dynamics and the function of
SARS-CoV-2 glycoproteins.68−76 The atomistic models of a
full-length SARS-CoV-2 S protein in a viral membrane allowed
for the simulation studies of the SARS-CoV-2 S trimer
structures in a glycosylated environment.69 All-atom molecular
dynamics (MD) simulations of the full-length SARS-CoV-2 S
glycoprotein embedded in the viral membrane, with a
complete glycosylation profile, provided significant structural
insights into functional spike conformations and mechanisms
of transitions70−73 Multimicrosecond MD simulations with
four full-length fully glycosylated S proteins characterized
structural and dynamic signatures of antibodies and vaccine
epitopes.74 We integrated coarse-grained and atomistic MD
simulations with network modeling to reveal that the SARS-
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CoV-2 S proteins can function as allosterically regulated
dynamic machines that exploit the plasticity of functional
regions exposed to binding with ACE2 and interacting proteins
to fine-tune differential responses to antibody binding.77−82
These studies showed that examining the allosteric behavior of
the SARS-CoV-2 S proteins may be useful to rationalize the
growing body of diverse experimental data. A critical review of
computational studies of the SARS-CoV-2 S proteins high-
lighted the synergies between experiments and simulations,
outlining directions for computational biology research in
understanding the mechanisms of COVID-19 protein targets.83
In this study, we combine atomistic simulations with the
ensemble-based mutational profiling of binding of the SARS-
CoV-2 S-RBD complexes with a wide range of nanobodies to
identify dynamic and binding affinity fingerprints and
characterize the energetic determinants of nanobody-escaping
mutations. Using an in silico mutational profiling approach for
probing the protein stability and binding, we examine
dynamics and energetics of the SARS-CoV-2 complexes with
single nanobodies Nb6 and Nb20, VHH E, a pair combination
VHH E + U, a biparatopic nanobody VHH VE, and a
combination of the CC12.3 antibody and VHH V/W
nanobodies. This study characterizes the binding energy
hotspots in the SARS-CoV-2 protein and complexes with
nanobodies providing a quantitative analysis of the effects of
circulating variants and escaping mutations on binding that is
consistent with a broad range of biochemical experiments. Our
results suggest a plausible mechanism in which nanobody
combinations and biparatopic nanobodies can elicit an
increased binding affinity response and yield resilience to
common escape mutants.
■ RESULTS AND DISCUSSION
Conformational Dynamics and Distance Fluctuation
Stability Analysis of the SARS-CoV-2 S RBD Complexes
Reveal Nanobody-Induced Modulation of Spike Plasti-
city. MD simulations of the SARS-CoV-2 S-RBD protein
complexes with a panel of nanobodies (Figure 1) examined
how nanobody binding targeting distinct binding epitopes can
change the dynamics of the RBD regions. A comparative
analysis of the conformational flexibility profiles revealed
nanobody-induced stabilization of the interacting regions,
especially in the complex with the biparatopic nanobody VHH
VE (Figure 2A). The RBD core regions including the α-helical
segments of the RBD (residues 349−353, 405−410, and 416−
423) and central β strands (residues 354−363, 389−405, and
423−436) showed only very small thermal fluctuations (Figure
2A, Supporting Information, Figure S1). Interestingly, the
antiparallel β-sheets β5 and β6 (residues 451−454 and 491−
495) also showed an increased stabilization. These structural
elements of the RBD are involved in linking the central core
with the more flexible RBM region and could serve as
important anchors of dynamic communication between
structurally stable and dynamic RBD region fluctuations
(Supporting Information, Figure S1). The stabilization of
these regions in the SARS-CoV-2 S complexes is particularly
important due to structural proximity to the sites of common
mutational escape L452, F486, and F490 (Supporting
Information, Figures S1 and S2). Conformational dynamic
profiles reaffirmed the stability of the α-helical segments in the
RBD that are located near the cryptic binding epitope
(residues 369−384) targeted by VHH U/V/W nanobodies
(Supporting Information, Figures S2 and S3). These residues
provide a stable anchoring platform for nanobodies binding to
the cryptic epitope, allowing for the modulation of RBD
flexibility and optimization of binding interactions with the
more dynamic RBD-binding epitope (Figure 2). The S-RBD
region also contains eight conserved cysteine residues, six of
which form three disulfide linkages (C336−C361, C379−
C432, and C391−C525), which provide support to the β-sheet
structure in the S-RBD core (Supporting Information, Figures
S2 and S3). Conformational dynamics of the biparatopic
nanobody complex VHH VE showed a significant stabilization
of the S-RBD regions and displayed the markedly reduced
fluctuations in the flexible RBM regions that become more
rigid and contribute to the binding interactions (Figure 2A).
The important functional sites E484, F486, and N501 belong
to flexible RBM regions but through binding contacts with
nanobodies become more stable in the complexes (Supporting
Information, Figures S2 and 2C−E). Interestingly, these
positions are commonly shared sites of nanobody-escaping
mutations and only the biparatopic nanobody showed
resilience to mutational escape in these positions. At the
same time, an appreciable level of flexibility was seen for the S-
RBD complexes with Nb20 (Figure 2B) and VHH E (Figure
2C) in regions that are distant from the RBM-binding epitope
(residues 359−372 and 380−390).
Another RBD region that remained flexible in the SARS-
CoV-2 complexes with the nanobodies is the tip of the RBM
loop (residues 473−483) (Figure 2). While the functional sites
E484, F486, and N501 belong to the intrinsically mobile RBM
regions, these residues are involved in binding contacts with
nanobodies Nb20 and VHH E, leading to their stabilization in
the complexes (Figure 2, Supporting Information, Figure S2).
Of some importance is a differential stabilization of the N501
residue that retained some degrees of mobility in the S-RBD
complexes with Nb20 (Figure 2C) and VHH E (Figure 2D)
but exhibited an increased stabilization in the complex with the
Figure 1. Crystal structures of the SARS-CoV-2 S trimer structures
used in this study included complexes with Nb6 (A), Nb20 (B), VHH
E (C), a nanobody combination pair VHH E/VHH U (D),
biparatopic nanobody VHH VE (E), CC12.3/VHH V pair (F), and
a CC12.3/VHH W pair (G). The S-RBD are in green surfaces. The
binding epitope residues are in the red surface. The bound
nanobodies are in magenta ribbons and annotated. The heavy chain
of CC12.3 is in blue color and light chain in cyan color. The sites
K417, L452, E484, and N501 subjected to circulating mutational
variants are shown in the cyan surface and annotated.
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biparatopic nanobody VHH VE (Figure 2E). Structural maps
of the conformational mobility profile also highlighted a
generally observed reduction of mobility for regions proximal
to the binding epitopes (Figure 2E, Supporting Information,
Figure S2). Conformational dynamic profiles highlighted some
interesting changes in protein mobility near the cryptic epitope
targeted by VHH U/V/W nanobodies (Figure 2C−F). We
observed that the stability of this region increased in the S-
RBD complex with a single VHH E nanobody that binds to a
flexible RBM epitope. Hence, VHH E binding may allosteri-
cally modulate stability in the distant epitope (Figure 2C).
This effect may facilitate couplings between distant epitopes
and promote binding avidity in the SARS-CoV-2 complexes
with VHH E/VHH U combination and the VHH VE
biparatopic nanobody.
The most common way for viruses to escape nanobody
blockage is by mutating residues in the easily accessible regions
where viruses can tolerate mutations while escaping immune
challenge. Conformational dynamic analysis suggested that
structural stabilization of the S-RBD regions induced by the
VHH VE biparatopic nanobody can effectively suppress the
mutational escape by reducing flexibility in the two remote
epitopes, which may reduce the virus potential for adaptability
in the functionally relevant for binding regions. A different
pattern of dynamic changes was seen in the S-RBD complexes
with CC12.3/VHH V and CC12.3/VHH W pairs (Figure 2B).
In some contrast, the entire RBD interface showed a
considerable stabilization owing to a dense network of specific
interactions formed by the CC12.3 antibody. On the other
hand, a very similar dynamic profile is seen in a second binding
epitope targeted by VHH V and VHH W nanobodies (Figure
2B). Of particular importance is the stability of binding
interactions formed by the loop in the distal end of RBD
(residues 473−488). The antibody-induced stability of the
distal loop is specific for CC12.3 binding as opposed to VHH
E- or Nb20-binding interactions. Structural maps depicted the
greater stabilization of the RBM region in the complex with the
CC12.3/VHH V pair, as compared to other complexes,
indicating stronger modulation of stability by the antibody
binding (Figure 2E,F).
The correlation matrix of the S-RBD complex with VHH E
showed that the S-RBD binding interface residues can be
anticorrelated with the fluctuations of VHH E residues
(Supporting Information, Figure S4). In the complex with
the VHH VE biparatopic nanobody, the S-RBD dynamic
couplings are generally stronger and positively correlated with
Figure 2. Conformational dynamics of the SARS-CoV-2 S-RBD. (A) Root-mean-square fluctuations (RMSFs) for MD trajectories of the SARS-
CoV-2 S-RBD complex with Nb20 (in green), VHH E (in maroon), and VHH VE (in magenta lines). (B) RMSF profile for the MD trajectories of
S-RBD binding with the CC12.3/VHH V pair (in green) and CC12.3/VHH W (in maroon). Conformational mobility maps for S-RBD complexes
with Nb20 (C), VHH E (D), VHH VE (E), and CC12.3/VHH V (F). The mobility level is in a color-coded scale from rigid in blue to flexible in
red. The nanobodies are shown in black-colored cartoons.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://doi.org/10.1021/acsomega.1c03558
ACS Omega XXXX, XXX, XXX−XXX
D
fluctuations of the VHH V at the cryptic site while mostly
anticorrelated with VHH E (Supporting Information, Figure
S4). The movements of VHH E and VHH V are dynamically
strongly coupled and anticorrelated. The positive correlations
between fluctuations of the S-RBD and VHH V residues could
be seen for the complex with the CC12.3/VHH V complex,
but weaker couplings were observed between S-RBD and
CC12.3 (Supporting Information, Figure S4). The presence of
strong positive correlations between S-RBD and VHH V
residues reflected a considerable stabilization of the binding
interface at the cryptic epitope. Based on these observations, it
is tempting to speculate that this epitope can act as a structural
anchor and global hinge of functional movement in the
complexes with the biparatopic nanobody VHH VE. The
results suggest that the structural stability of the S-RBD
induced by VHH VE may be linked to experimentally observed
avidity effects when multiple interactions in different epitopes
can synergize and enhance the strength of protein−protein
interactions in the multivalent complex, thus providing the
thermodynamic advantage for stronger binding and neutraliza-
tion capacity.84−86
Modulation of Functional Dynamics by Nanobody
Binding: Mutational Escape Sites Are Hinge Centers of
Collective Motions. By using principal component analysis
(PCA) of the atomistic trajectories, we quantified the pattern
of collective motions in the SARS-CoV-2 S-RBD complexes
(Figure 3). The low-frequency modes are often functionally
important as perturbations induced by mutations or binding
can evolve along the pre-existing slow modes to elicit specific
protein responses. As may be expected given a similar
topological arrangement of the SARS-CoV-2 S protein fold,
the essential profiles displayed a similar shape in the complexes
with nanobodies (Figure 3). The distributions of S-RBD
complexes with Nb20, VHHE, and VHHE/VHH/U nano-
bodies (Figure 3A−C) revealed that sites of circulating variants
K417 and N501 are often aligned with the local maxima
corresponding to moving regions, while the L452 position
belongs to the hinge region that is mostly immobilized in
cooperative motions. A common sharp bifurcated peak was
observed at the flexible region (residues 475−486), while the
periphery of the nanobody-binding epitopes particularly E484
position is aligned with the local minimum in this region. A
comparison of slow-mode profiles for the S-RBD complexes
with nanobodies revealed several well-defined hinge regions,
including hinge clusters that are anchored by G447/Y449
residues and also L452 and L455 positions (Figure 3B−D).
Another noticeable hinge cluster includes residues F490, L492,
S494, G496, N501, and Y505. Both residue clusters are located
in the relatively flexible regions of the S-RBD but become
largely immobilized in the complexes.
Interestingly, most of the sites of escaping mutations belong
to the hinge clusters and may be involved in control of
collective motions in the complexes. Indeed, the escape
mutations in the VHH E interface featured G447S, Y449H/
D/N, L452R, F490S, S494P/S, G496S, and Y508H
modifications.61 We also observed that residues in the cryptic
binding epitope Y369, S371, F374, and F377 are aligned with
conserved hinge positions. Our analysis suggested that these
hinge clusters from distant binding epitopes may cooperatively
regulate the functional dynamics of the SARS-CoV-2 S-RBD
complexes with nanobodies. Instructively, the residues in the
moving region near E484/F486 RBD positions were aligned
with the local maxima of the essential mobility profiles in the
complexes with VHH E/VHH U (Figure 3C) and VHH VE
Figure 3. Collective dynamic profiles of the SARS-CoV-2 S complexes for Nb20 (A), VHH E (B), VHH E/VHH U (C), VHH VE (D), CC12.3/
VHH V (E), and CC12.3/VHH W (F). The profiles represent the mean-square displacements in functional motions averaged over the three lowest
frequency modes. The slow-mode profiles are shown in maroon-colored lines with individual data points highlighted in filled orange circles. The
slow-mode profile for the S-RBD complex with ACE2 is shown for comparison in turquoise color lines.
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biparatopic nanobodies (Figure 3D). This flexible region that
harbors important sites of escape mutations is involved in the
propagation of collective dynamic motions. As a result,
mutations in these positions may not only have effect on
local dynamic changes but also alter cooperative conforma-
tional changes in the S protein and compromise the fidelity of
protein response to nanobody binding.
The slow-mode profiles for the S-RBD complexes with
CC12.3/VHH V and CC12.3/VHH W pairs showed a distinct
pattern (Figure 3E,F). The shallow minima region in the
RBM-binding epitope harbored E484 and N501 positions
aligned in a largely immobilized manner in collective
movement regions. We also noticed that the experimentally
known sites of escaping mutations for CC12.3 antibodies60
such as Y421, L455, F456, and Y508 corresponded to the local
minima of the profile. According to the observed profile of
collective motions, the emergence of shallow local minima
regions may reflect some degrees of tolerance to mutations at
individual positions as these changes would not significantly
affect the pattern of functional dynamics.
The central finding of this analysis is that escape mutations
can arise in the clusters of stable hinge sites and in the flexible
RBM positions that belong to the moving regions along slow
modes. Collectively, these residues are involved in coordina-
tion and execution of functional spike movements and dynamic
control of binding. Local perturbations in structurally stable
anchor positions can result in cascading dynamic changes and
produce maximum response in the functionally active sites. At
Figure 4. Mutational profiling of the SARS-CoV-2 S binding with nanobodies. (A) Mutational scanning heatmap for the SARS-CoV-2 S complex
with the Nb6 nanobody. (B) Residue-based folding stability analysis of the SARS-CoV-2 S-RBD complex with Nb6. (C) Structural map of the S-
RBD-binding epitope in the complex with Nb6. The S-RBD is shown in the green surface. The epitope residues are shown in red and the binding
energy hotspots are shown in the blue surface. The positions of K417, L452, E484, and N501 are shown in black color and annotated. (D)
Mutational scanning heatmap for the SARS-CoV-2 S complex with the Nb20 nanobody. (E) Residue-based folding stability analysis of the S-RBD
complex with Nb20. (F) Structural map of the S-RBD-binding epitope in the complex with Nb20. The annotations for the epitope residues and the
binding energy hotspots are shown in C. (G) Mutational scanning heatmap for the SARS-CoV-2 S complex with the VHH E nanobody, PDB id
7B14. (H) Residue-based folding stability analysis of the S-RBD complex with the VHH E nanobody. (I) Structural map of the S-RBD-binding
epitope in the complex with the VHH E nanobody. The heatmaps show the computed binding free energy changes for 19 single mutations on the
binding epitope sites. The squares on the heatmap are colored using a three-colored scalefrom light blue to red, with red indicating the largest
unfavorable effect on binding. The data bars correspond to the binding free energy changes, with the positive value shown by bars toward the right
end of the cell and negative favorable values as bars oriented toward the left end. The standard errors of the mean for binding free energy changes
were based on five independent trajectories, and different numbers of selected samples from a given trajectory (500, 1000, and 2000 samples) are
∼0.2−0.25 kcal/mol using averages over different trajectories and ≤0.15 kcal/mol from computations based on different numbers of samples from
a single trajectory.
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the same time, dynamic perturbations caused by escape
mutations in residues from globally moving regions can initiate
fast response along slow normal modes and trigger collective
allosteric changes due to cooperativity. Combined with the
conformational dynamic analysis, the results suggested that
dynamic couplings between the clusters of residues targeted by
escaping mutants could determine functional protein response
and dictate a mechanism of the nanobody binding.
Mutational Scanning Identifies Binding Affinity
Hotspots and Clarifies Energetic Drivers of Nanobody-
Escaping Mutations. We explored in silico mutational
scanning based on the equilibrium ensembles of conformations
to systematically profile the S-RBD residues and compute the
binding free energy changes caused by amino acid
modifications for studied SARS-CoV-2 S-RBD complexes
with nanobodies. The mutational heatmaps provided a visual
representation of screening, pointing to the S-RBD residues
with high sensitivity to modifications and therefore considered
as potential binding energy hotspots. We also used the FoldX
approach with the all-atom representation of the protein
structure87−90 to simultaneously evaluate the folding free
energies for the S-RBD residues and identify hotspots of
protein stability in the complexes. The protein stability ΔΔG
changes were computed by averaging the results over 1000
trajectory samples.91,92
Mutational analysis of the S-RBD binding with Nb6 revealed
binding energy hotspots for the group of hydrophobic residues
(Y449, L453, L455, F456, G485, Y489, F490, G496, and
Y505) that were experimentally confirmed as important
residues for ACE2 binding in deep mutagenesis scanning
(Figure 4A,B).39 Our results indicated that a strong similarity
in the interaction pattern with ACE2 may provide the
energetic advantage for the Nb6 nanobody to competitively
inhibit the ACE-binding region. The folding free energies of
the S-RBD residues accurately reproduced stability of the
conserved RBD core (Figure 4B). The negative folding free
energies were seen for the binding energy hotspots Y449,
L455, F456, G485, Y489, and Y505, suggesting that these
hydrophobic sites play an important role in both protein
stability and binding with the nanobody. This may explain why
escape mutations produced by virus tend to “avoid” these
positions that are central for the RBD integrity and productive
binding to the host receptor. Structural map of the binding
epitope residues showed that K417, L452, E484, and N501 are
located in the immediate proximity of the binding hotspot
residues (Figure 4C). Interestingly, mutational scanning also
reproduced sensitivity of sites targeted by common resistant
mutations of many individual nanobodies (F490S, E484K,
Q493K, F490L, F486S, F486L, and Y508H).58 In particular,
E484, F486, and F490 positions appeared to be highly sensitive
to Nb6 binding (Figure 4A−C). The binding energy hotspots
in the complex with the Nb20 nanobody corresponded to
residues Y449, Y453, V483, Y489, F490, and Q493 (Figure
4D). We found a number of commonly shared hotspots for
Nb6 and Nb20 nanobodies including Y449, F456, Y489, and
F490 (Figure 4D). The nanobody-specific binding hotspots for
Nb20 were aligned with V483, L492, and Q493 residues
(Figure 4D).
Figure 5. Mutational sensitivity analysis for the SARS-CoV-2 S complexes with Nb6 and Nb20 nanobodies. (A−C) Distribution of binding free
energy changes caused by mutations of K417, E484, and N501 sites in the S-RBD complexes with the Nb6 nanobody. (D−F) Distribution of
binding free energy changes caused by mutations of K417, E484, and N501 sites in the S-RBD complexes with the Nb20 nanobody. The computed
standard errors of the mean for the binding free energy changes based on different numbers of selected samples from a given trajectory (500, 1000,
and 2000 samples) are 0.1−0.2 kcal/mol.
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In agreement with the experimental studies, mutational
scanning analysis showed that F490, E484, F486, and Q493
positions can be important sites of escaping mutations for Nb6
and Nb20 nanobodies (Figure 4A,D). Several clusters of
binding energy hotspots were found for the S-RBD complex
with the VHH E nanobody (Figure 4G−I). The first included
sites L452, Y453, and F456, while the second cluster included
functional positions G485, F486, Y489, F490, L492, G496, and
Q498. We specifically focused on the mutational profiling of
K417, E484, and N501 sites targeted by global circulating
mutations (Figure 5). Amino acid substitutions in K417 and
N501 positions produced relatively small changes in Nb6
binding, while most of the mutations at E484 yielded strong
unfavorable effects on binding affinity (Figure 5A−C).
Notably, mutations of the E484 residue resulted in a significant
loss of binding affinity (>2.0 kcal/moll) for both Nb6 and
Nb20 nanobodies, while the respective modifications are
known to improve binding with the host receptor (Figure 5).
In the complex with Nb20, E484D/K/Q mutations appeared
to be highly unfavorable for binding, resulting in >2.5 kcal/mol
losses in the binding affinity (Figure 5E). Consistent with the
results of mutational scanning, the engineered charge reversal
on R31 (R31D) is unable to recover the salt bridge and restore
binding to the E484K mutant.56,57 At the same time, the
N501Y mutation led to the moderately increased binding
affinity (Figure 5F). Structural mapping of protein stability
hotspots for Nb6 and Nb20 nanobodies highlighted distinct
conserved clusters of residues localized at the center of the
RBM-binding epitope and in the S-RBD core region near the
cryptic binding epitope (Supporting Information, Figure
S5A,B). Collectively, these observations are in agreement
with the experimental studies showing that E484 on the RBD
is the “Achilles heel” of the ultrapotent Nb20 and Nb21
nanobodies.56,57 These results strongly support the notion that
functional and structural plasticity can be important to
mechanisms by which mutations can alter the antigenic
responses and elicit antibody evasion. Indeed, we found that
the sites of mutational escape to nanobodies corresponded to
flexible energetic centers that are involved in the network of
local binding interactions and execution of functional
cooperative movements in response to binding. As a result,
mutations in these positions could have strong cumulative
effects by compromising nanobody recognition and binding
affinity as well as affecting functional dynamics and protein
Figure 6. Mutational scanning heatmap for the SARS-CoV-2 S complex with VHHE/VHH U combination of nanobodies, PDB id 7KN5 (A).
Folding stability analysis of the S-RBD complex with VHH E/VHH U combination (B). Mutational scanning heatmap for the S-RBD complex with
the VHH VE biparatopic nanobody, PDB id 7B17 (C). Residue-based folding stability analysis of the S-RBD complex with VHH VE (D).
Mutational scanning heatmap for the SARS-CoV-2 S complex with CC12.3/VHH V combination, PDB id 7KN6 (E). Folding stability analysis of
the S-RBD complex with CC12.3/VHH V antibody/nanobody combination (F). The heatmaps show the computed binding free energy changes
for 19 single mutations on the binding epitope sites. The squares on the heatmap are colored using a three-colored scalefrom light blue to red,
with red indicating the largest unfavorable binding changes.
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response to perturbations. These results support the recent
study suggesting that functional plasticity is instrumental to
allosteric communications in proteins where structural stability
centers cooperate with more dynamic allosteric hotspots that
correspond to structurally adaptable and moderately conserved
protein positions.93
Binding Footprints for Nanobody Combinations at
Distinct Epitopes Reveal Changes in the Mutational
Landscape and Increased Resilience to Escape Muta-
tions. We also identified binding affinity fingerprints for the
SARS-CoV-2 S-RBD complexes with a nanobody combination
VHH E/VHH U targeting different epitopes (Figure 6A,B)
and the biparatopic nanobody VHH VE that has two antigen-
binding sites in one molecule and obtained by fusing
nanobodies that targeted distinct epitope regions (Figure
6C,D). For the S-RBD complex with the nanobody pair
VHHE/VHH U, the number of RBD residues involved in the
favorable binding interactions increased, but the number of
binding energy hotspots remained similar to that of the
complexes with single nanobodies (Figure 5A). The S-RBD
hotspot residues were aligned with the same group of residues
Y449, F486, Y489, F490, and Y508 (Figure 5A). In agreement
with the experiments,61 mutations at the VHH E interface
Y449H/D/N, F490S, S494P/S, G496S, and Y508H produced
large unfavorable ΔΔG changes >2.0 kcal/mol (Figure 6A,B).
A number of hotspot positions were also observed in the
second cryptic epitope including conserved and stable residues
Y369, S371, F374, and F377.
Mutational scanning analysis also showed that escaping
mutations Y369H, S371P, F374I/V, T376I, F377L, and
K378Q/N at the VHH U interface resulted in considerable
binding losses with ΔΔG ∼ 2.5 kcal/mol/(Figure 6A,B). In
the complex with the biparatopic nanobody VHH VE (Figure
6C,D), the pattern remained generally similar, pointing to a
strong contribution of residues F377, C379, Y449, F486, Y489,
L490, and L492. The binding interactions in the cryptic
epitope are determined by RBD core residues 369−384. Of
importance are strong contributions of F377, C379, and Y380
residues acting as rigid binding energy hotspots (Figure 6C).
Many of the binding hotspot centers for complexes with the
VHH E/VHH U pair and VHH VE corresponded to
conserved centers of protein stability (Figure 6A−D) where
mutations could affect the RBD folding stability, partly
explaining why these nanobodies can suppress the emergence
Figure 7. Mutational sensitivity analysis for the SARS-CoV-2 S complexes with VHH E, VHH VE nanobodies, and CC12.3/VHH V antibody/
nanobody combination. (A−C) Distribution of binding free energy changes caused by mutations of K417, E484, and N501 sites in the S-RBD
complexes with the VHH E nanobody. (D−F) Distribution of binding free energy changes caused by mutations of K417, E484, and N501 sites in
the S-RBD complexes with the VHH VE biparatopic nanobody. (G−I) Distribution of binding free energy changes caused by mutations of K417,
E484, and N501 sites in the S-RBD complexes with CC12.3/VHH V antibody/nanobody combination. The standard errors of the mean for the
binding free energy changes are 0.15−0.2 kcal/mol.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://doi.org/10.1021/acsomega.1c03558
ACS Omega XXXX, XXX, XXX−XXX
I
of escaping variants. Even though these nanobodies make
contacts with sites of circulating variants K417, L452, and
E484, these positions can be quite tolerant to mutations
(Figure 6C,D). This is consistent with the observed
effectiveness of the nanobodies against many antigenic
variants.61 The results also indicated that only moderately
flexible RBD sites F486 and F490 are consistently featured as
common binding energy hotspots for these complexes, which
may explain why escape mutants in these positions are known
to dominate at the VHH E interface.61 The important finding
of this analysis is that mutational sensitivity of the binding
hotspots in the RBM epitope can be attenuated in the complex
with the biparatopic nanobody. This may contribute to the
increased resilience of the VHH VE engineered nanobody to
mutational escape. The mutational heatmaps of the S-RBD
binding with antibody CC12.3 combinations with VHH V and
VHH W nanobodies (Figure 6E,F) recapitulated the
experimentally known sites of escaping mutations Y421,
L455, F456, and Y508 for CC12.3.60
The computed standard errors of the mean for the binding
free energy changes were ∼0.13−0.22 kcal/mol using averages
over different trajectories and within 0.1 kcal/mol from
computations based on different numbers of samples from a
single trajectory. A more detailed analysis of mutational
changes in sites of circulating variants showed that VHH E and
VHH VE nanobodies retained their binding affinity to
mutations in K417 and N501 positions and remained relatively
forgiving to E484 mutations (Figure 7A−F). Our analysis
correctly captured a considerably better tolerance of these
nanobodies to E484K/D mutations that are sensitive to the
ultrapotent Nb20 and Nb21 class I nanobodies (Figure 5).56,57
According to our analysis, binding of CC12.3/VHH V and
CC12.3/VHH W combinations can result in even stronger
tolerance to mutations as only small binding energy differences
induced by mutations were found for these complexes (Figure
7G−I). This is consistent with the observed resilience of these
cocktails against these antigenic variants.61
Structural maps of the RBM-binding footprints showed that
sites of circulating variants are located at the edges of the
binding hotspot regions, and therefore, mutations in these
positions appeared to have a relatively moderate effect on
binding (Figure 8). Of importance are only minor overlaps of
the critical E484 site with the regions involved in binding with
VHH E and VHH VE nanobodies (Figure 8D,E). Even more
instructive are the structural maps for CC12.3/VHH V
antibody/nanobody combination (Figure 8C,F). In this case,
the E484 site has no direct overlap with the binding hotspot
regions, while other positions K417 and N501 are only
peripherally involved in the interaction footprint. The large
binding epitope and broadly distributed binding hotspot
positions can enable high affinity while inducing the increased
resilience of these synergistic cocktails to common escape
mutants. Structural mapping showed a significant coverage of
the binding energy hotspots at the second binding epitope.
Our results suggest that binding to stable RBD core residues in
this site can be leveraged by the biparatopic nanobody and
antibody/nanobody combination as a regulatory anchor that
firmly immobilizes nanobodies at the cryptic binding site and
facilitates binding of the VHH E arm at the RBM epitope at a
smaller entropic cost. This suggests a plausible mechanism by
which biparatopic nanobodies can leverage dynamic couplings
between distinct binding epitopes to enhance binding and
mitigate mutational escape.
We also evaluated the correlations between binding free
energy changes of the S-RBD residues with ACE2 and studied
nanobodies (Figure 9). A consistent correlation (Pearson
correlation coefficient R ∼ 0.7−0.85) was found between the
effects of RBD mutations on binding with ACE2 and the
nanobodies. This indicated that the nanobodies can efficiently
mimic the binding energetics of the host receptor. We
specifically highlighted the binding free energy changes
associated with mutations at sites of circulating variants
K417, L452, E484, and N501 (Figure 9). While mutations in
these positions tend to cause similar and moderate binding
energy changes for ACE2 and nanobodies, there was some
dispersion of energetic changes showing a larger unfavorable
effect on nanobody binding (∼1.0−1.5 kcal/mol) than on
ACE2 binding (∼0.5 kcal/mol) (Figure 9A−C). A very strong
correlation was seen between binding free energy changes in
these functional positions with ACE2 and CC12.3/VHH V
combination (Figure 9D). This may reflect a high degree of
tolerance to mutations in sites of circulating variants,
suggesting that a combination of antibody and nanobody
binding may be very efficient in the suppression of mutational
escape. Hence, the results suggest that structural and dynamic
mimicry of the protein stability and binding interactions by the
nanobody combinations could limit the escaping potential for
the virus in sites of common circulating variants.
In Silico Profiling of the SARS-CoV-2 Binding with
Nanobodies and Predicted Mutational Escape Land-
scape: A Comparison with Mutagenesis Experiments.
The results of our study provided a quantitative character-
ization of the SARS-CoV-2 S binding with a panel of
nanobodies that agrees with a wide spectrum of mutagenesis
and biophysical experiments. Here, we summarize our findings
and their connection with the available experimental data.
From the structural and dynamic analysis of SARS-CoV-2 S
Figure 8. Structure of the S-RBD complex with VHH E/VHH U (A),
complex with the biparatopic nanobody VHH VE (B), and CC12.3/
VHH V antibody/nanobody combination (C). The S-RBD is shown
in the green surface. The epitope residues are shown in red. The
positions of K417, L452, E484, and N501 are in light cyan color. Top
views of the binding epitopes for S-RBD complexes with VHH E/
VHH U (D), complex with biparatopic nanobody VHH VE (E), and
CC12.3/VHH V pair (F). The S-RBD is shown in the green surface.
The epitope residues are shown in red and the binding energy
hotspots are shown in the blue surface. The positions of K417, L452,
E484, and N501 are shown in black color and annotated.
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binding with the Nb6 nanobody, we found that Nb6 binding is
highly sensitive to modifications at the E484 site, particularly
E484K mutation leading to a significant loss of binding affinity.
Indeed, the experiments revealed that binding of the highly
potent Nb6 nanobody can be severely compromised by E484K
mutation, resulting in the loss of activity.55 The computed
mutational profiling maps indicated that the experimentally
known resistant mutations F490S, E484K, Q493K, F490L,
F486S, and F486L are indeed highly sensitive to Nb6 binding.
Hence, in silico mutational profiling reproduced the known
binding energy hotspots responsible for the high potency of
Nb6 and provided accurate predictions of nanobody-sensitive
positions and escape mutants. We also found that E484D/K/Q
mutations were highly unfavorable for Nb20 binding, while
L452R and L452K variants were less deleterious than the
modifications in E484. These results are in good agreement
with the mutagenesis studies of Nb20 binding,56 indicating
that amino acid substitutions in E484 and L452 sites can be
detrimental and allow virus by targeting these vulnerable sites
to elicit a strong escape from the nanobody.
In agreement with the experimental studies, in silico
mutational profiling accurately predicted F490, E484, F486,
and Q493 positions as common sites of escaping mutations for
both Nb6 and Nb20 nanobodies. Our results provided a
plausible rationale to the functional role of E484 as the
“Achilles heel” of the ultrapotent nanobodies as a range of
modifications in this site can dramatically reduce the affinity of
these class I nanobodies.55−57 Consistent with the functional
studies, we found that the binding of nanobodies Nb6, Nb20,
and VHH E can be impeded by perturbations at highly
antigenic sites in the RBM region (particularly E84 position)
as escape mutations tend to target these flexible positions
because of their effect on collective dynamic changes and
allosteric interactions. Of special interest is also a strong
agreement between computed mutational scanning profiles
and the experimentally observed pattern of escape mutations in
complexes with VHH E, VHH E/VHH U, and VHH VE
nanobodies. Consistent with the mutagenesis screens,61 our
results identified prominent escape mutations Y449H/D/N,
L452R, F490S, S494P, and Y508H in the VHH E interface, as
well as a group of escape mutations targeting in the conserved
sites of the RBD core (S371, F374, T3765, and F377) at the
VHH U interface.
In silico mutational scanning and the computed binding free
energy changes using the BeAtMuSiC approach94,95 showed a
good overall agreement with mutagenesis experiments,
indicating that the employed computational tools may be
particularly useful for the detection of hotspots of escape
Figure 9. Scatter plots of binding free energy changes for the S-RBD residues in complexes with ACE2 and VHH E (A), ACE2 and VHH E/VHH
U (B), ACE2 and VHH VE (C), and ACE2 and CC12.3/VHH V combination (D). The data points are shown as black-filled squares and scatter
points corresponding to the binding free energy changes in sites K417, L452, E484, and N501 are shown as orange-filled circles.
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mutations and identification of major mutations that are
deleterious for nanobody binding. The advantages of this
approach are fast and accurate predictions of the effect of
mutations on both the strength of the binding interactions and
on the stability of the complex using statistical potentials and
neural networks. This approach is comparable to other
knowledge-based structural methods such as Dcomplex96
which is based on distance-specific contact potentials trained
on the monomer structures. By combining structural and
evolutionary profile analyses derived from the binding
interfaces, the BindProfX approach97 showed potential for
improvements over both the statistics-based and physics-based
FoldX potentials.90−92 The BeAtMuSiC approach adapted in
our study that was further enhanced through ensemble-based
averaging of binding energy computations yielded a good
correlation between prediction and experiments and was
successfully used for the binding free analysis of the SARS-
CoV-2 S binding with the host receptor77 and antibodies.80−82
The recent analysis of computational tools for estimating
protein−protein binding probed several approaches or their
predictive ability of relative binding affinities for 654 single
mutations on antibody−antigen and nonantibody−antigen
complexes.98 Instructively, this analysis showed context-
dependent and system-dependent strengths and weaknesses
of these tools. Moreover, physics-based methods often display
a similar predictive power to comparable but much faster
knowledge-based methods which are indispensable for massive
mutational scanning experiments.98 Importantly, it was
concluded that most methods can quickly and accurately
differentiate between favorable and unfavorable mutations
rather than accurately predicting the actual binding affinities.98
Our results concur with these observations showing that the
rapid in silico profiling of mutations for the SARS-CoV-2 S
protein complexes can yield a fairly robust assessment of major
variants and suggest structural basis for changes in the protein
stability and binding. Interestingly, a recent large-scale in silico
mutagenesis study using the BeAtMuSiC approach profiled all
possible point mutations in the RBD residues on its stability
and binding with antibodies and ACE2 receptors, showing that
predictions agreed well with various experimental, epidemio-
logical, and clinical data.99 It is worth stressing that more
rigorous physics-based approaches may yield more accurate
predictions of binding affinity, but the requirements for
adequate sampling and comprehensive scanning of protein
residues make this strategy less plausible in practice. Instead,
our approach by combining atomistic simulations and
knowledge-based models of protein binding provided the
ensemble-average estimates of the binding free energy changes
allowing for a comprehensive scanning and meaningful
interpretation of the SARS-CoV-2 S binding with nanobodies.
■ CONCLUSIONS
We combined atomistic simulations with the ensemble-based
mutational profiling of binding interactions for a diverse panel
of SARS-CoV-2 S-RBD complexes with nanobodies. The
analysis of collective dynamics in the nanobody complexes
showed that escape mutations at the RBM epitope may emerge
in the intrinsically dynamic positions that become less flexible
upon binding and play an important regulatory role in
coordination of functional motions. Using the in silico
mutational profiling approach for probing the protein stability
and binding, we examine dynamics and energetics of the
SARS-CoV-2 complexes with single nanobodies Nb6 and
Nb20, VHH E, a pair combination VHH E + U, a biparatopic
nanobody VHH VE, and a combination of the CC12.3
antibody and VHH V/W nanobodies. This study characterizes
the binding energy hotspots in the SARS-CoV-2 protein and
complexes with nanobodies providing a quantitative analysis of
the effects of circulating variants and escaping mutations on
binding that is consistent with a broad range of biochemical
experiments. The results also revealed that the biparatopic
nanobody can use binding at the cryptic binding site to
establish a structurally stable regulatory “anchor” that mediates
dynamic couplings between nanobody arms and provides
allosteric control over structural changes in the RBM epitope.
This suggests a plausible mechanism by which biparatopic
nanobodies can leverage dynamic couplings to synergistically
inhibit distinct binding epitopes and suppress mutational
escape. We argue that mutational escape mechanisms may be
controlled through structurally adaptable binding hotspots in
the receptor-accessible binding epitope that are dynamically
coupled to the stability centers in the distant binding epitope
targeted by VHH U/V/W nanobodies. These results may
prove to be useful to identify the emergent strains of concern,
better understand, and combat the escaping mutation
mechanisms which may aid in the rational design of new
vaccines and nanobody/antibody combinations.
■ METHODS
MD Simulations. All structures were obtained from the
Protein Data Bank.100,101 Hydrogen atoms and missing
residues were initially added and assigned according to the
WHATIF program web interface.102 The structures were
further preprocessed through the Protein Preparation Wizard
(Schrödinger, LLC, New York, NY). The missing loops in the
cryo-EM structures were also reconstructed using template-
based loop prediction approaches ArchPRED.103 The side
chain rotamers were refined and optimized by the SCWRL4
tool.104 The protein structures were subsequently optimized
using atomic-level energy minimization with a composite
physics and knowledge-based force fields using the 3Drefine
method.105 The shielding of the receptor binding sites by
glycans is an important feature of viral glycoproteins, and
glycosylation on SARS-CoV-2 proteins can camouflage
immunogenic protein epitopes.106,107 The structure of glycans
at important glycosites of the closed and open states of SARS-
CoV-2 S protein was previously determined in the cryo-EM
structures of the SARS-CoV-2 spike S trimer in the closed state
(PDB id 6VXX) and open state (PDB id 6VYB). These glycans
were incorporated in simulations in addition to the
experimentally resolved glycan residues present in the cryo-
EM structures of studied SARS-CoV-2 S proteins.
All-atom 1 μs MD simulations have been performed for all
studied protein structures. The structures of the SARS-CoV-2
S trimers were simulated in a box size of 85 × 85 × 85 Å with a
buffering distance of 12 Å. Assuming normal charge states of
ionizable groups corresponding to pH = 7, sodium (Na+) and
chloride (Cl−) counter ions were added to achieve charge
neutrality, and a salt concentration of 0.15 M NaCl was
maintained. All Na+ and Cl− ions were placed at least 8 Å away
from any protein atoms and from each other. All-atom MD
simulations were performed for an N, P, T ensemble in the
explicit solvent using the NAMD 2.13 package108 with the
CHARMM36 force field.109 The nonbonded van der Waals
interactions were computed using an atom-based cutoff of 12
Å with switching van der Waals potential beginning at 10 Å.
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Long-range electrostatic interactions were calculated using the
particle mesh Ewald method.110 All atoms of the complex were
first restrained at their crystal structure positions with a force
constant of 10 Kcal mol−1 Å−2. Equilibration was done in steps
by gradually increasing the system temperature in steps of 20 K
starting from 10 K until 310 K and, at each step, 1 ns
equilibration was done maintaining a restraint of 10 Kcal mol−1
Å−2 on the protein Cα atoms. After the restraints on the
protein atoms were removed, the system was equilibrated for
an additional 10 ns. An NPT production simulation was run on
the equilibrated structures for 500 ns maintaining the
temperature at 310 K and a constant pressure (1 atm). In
simulations, the Nose−Hoover thermostat111 and isotropic
Martyna−Tobias−Klein barostat112 were used to maintain the
temperature at 310 K and pressure at 1 atm, respectively.
We performed PCA of reconstructed trajectories derived
from CABS-CG simulations using the CARMA package113 and
also determined the essential slow-mode profiles using elastic
network model (ENM) analysis.114−116 Two ENMs: Gaussian
network model (GNM) and anisotropic network model
(ANM) approaches were used to compute the amplitudes of
isotropic thermal motions and directionality of anisotropic
motions. The functional dynamic analysis was conducted using
the GNM in which the protein structure is reduced to a
network of N residue nodes identified by Cα atoms and the
fluctuations of each node are assumed to be isotropic and
Gaussian. Conformational mobility profiles in the essential
space of low-frequency modes were obtained using the ANM
server116 and DynOmics server.117
Mutational Scanning and Sensitivity Analysis. We
conducted mutational scanning analysis of the binding epitope
residues for the SARS-CoV-2 S protein complexes. Each
binding epitope residue was systematically mutated using all 19
substitutions, and the corresponding protein stability changes
were computed. The BeAtMuSiC approach94,95 was employed
that is based on statistical potentials describing the pairwise
interresidue distances, backbone torsion angles, and solvent
accessibilities and considers the effect of the mutation on the
strength of the interactions at the interface and on the overall
stability of the complex. The binding free energy of the
protein−protein complex can be expressed as the difference in
the folding free energy of the complex and folding free energies
of the two protein binding partners
Δ = − −G G G Gbind
com A B
(1)
The change of the binding energy due to a mutation was
then calculated as follows





We leveraged rapid calculations based on statistical
potentials to compute the ensemble-averaged binding free
energy changes using equilibrium samples from MD
trajectories. The binding free energy changes were computed
by averaging the results over 1000 equilibrium samples for
each of the studied systems. The quality and robustness of
calculations are assessed in terms of standard errors of the
mean based on the five independent trajectories and
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Domains in the full-length SARS-CoV-2 S protein and a
detailed structural organization of the S-RBD, cysteine
residues that form disulfide linkages in the S-RBD
protein, structural organization of cysteine clusters in the
S2 subdomain of the SARS-CoV-2 spike prefusion
structure, covariance matrices of residue fluctuations in
the S-RBD complexes with nanobodies, and structural
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